Atea Pharmaceuticals Q2 EPS $(0.34) Beats $(0.47) Estimate
Portfolio Pulse from mahesh@benzinga.com
Atea Pharmaceuticals reported Q2 losses of $(0.34) per share, beating the analyst consensus estimate of $(0.47) by 27.66%. This represents a 10.53% increase over losses from the same period last year.
August 08, 2023 | 9:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Atea Pharmaceuticals' Q2 losses were less than expected, which could be seen as a positive sign by investors.
Atea Pharmaceuticals reported lower than expected losses for Q2, which could be interpreted as a positive sign by investors. This could potentially lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100